Elexacaftor is a CFTR potentiator and acts synergistically with ivacaftor during acute and chronic treatment

Cystic fibrosis (CF) is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR), which lead to early death due to progressive lung disease. The development of small-molecule modulators that directly interact with CFTR to aid in protein folding (“correctors”) and/or incr...

Descripción completa

Detalles Bibliográficos
Autores principales: Shaughnessy, Ciaran A., Zeitlin, Pamela L., Bratcher, Preston E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8494914/
https://www.ncbi.nlm.nih.gov/pubmed/34615919
http://dx.doi.org/10.1038/s41598-021-99184-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8494914/
https://www.ncbi.nlm.nih.gov/pubmed/34615919
http://dx.doi.org/10.1038/s41598-021-99184-1

Ejemplares similares